Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?

Anne-Sophie AS Michallet, Laure L Lebras, Deborah D Bauwens, Fadhela F Bouafia-Sauvy, Françoise F Berger, Christelle C Tychyj-Pinel, Anne A D’Hombres, Gilles G Salles and Bertrand B Coiffier

Abstract

Background: Less than 20% of patients with follicular lymphoma (FL) present with Ann Arbor Stage I or II disease at diagnosis. Numerous therapeutic options exist, however radiation therapy is considered the standard of care for early-stage disease based on single-institution or retrospective series. Our aim was to revisit the outcome of patients with localized FL in the rituximab era.

Patients and Methods: We analyzed the characteristics and outcomes of 145 early-stage FL patients, who were retrospectively divided into six groups according to their initial treatment: watchful waiting (WW), chemotherapy alone (CT), radiotherapy alone (RT), combined radiotherapy and chemotherapy (RT-CT), rituximab alone (Ri), and immunochemotherapy (Ri-CT).

Results: Of the 145 patients, 84 (57.9%) had stage I disease and 61 (42.1%) stage II. The complete response (CR) rate varied from 57% for the Ri group to 95% for the RT-CT group. Overall survival (OS) at 7.5 y of patients treated after 2000 was better than that of those treated prior to 2000. OS did not significantly differ from one treatment to another. In contrast, a significant difference was found for progression-free survival (PFS) at 7.5 y, which favored Ri-CT (60%) therapy versus the others (p=0.00135).

Conclusion: Delayed therapy initiation was associated with a similar OS than that observed in patients receiving immediate intervention. The “watchful waiting” strategy may thus be proposed as first-line therapy, similar to stage III and IV FL patients with a low tumor burden. However, when treatment is required, immunochemotherapy appears to be the best option.

Keywords: Follicular lymphoma, Chemotherapy, Complete response, Rituximab, Radiotherapy

Background

Follicular lymphoma (FL) is the most frequently encountered type of indolent lymphomas. Indolent lymphomas are considered to be an incurable malignancy with a relapsing and remitting course. For the vast majority of patients, the disease is managed over many years [1]. Most patients are diagnosed with FL at an advanced stage, with <20% presenting with either stage I or II. In the small proportion of patients (15-20%) diagnosed with localized Ann Arbor stage I or II disease, the treatment of choice remains poorly defined. A wide range of management options exists, from extended or involved field radiotherapy, which remained the mainstay treatment [2-4], to the use of combined radiochemotherapy [5,6] or the “watchful waiting” approach [7,8]. As there has been no randomized study, it is difficult to claim that one strategy is better than another [9]. An Italian expert panel published guidelines for the management of nodal indolent lymphomas [10]. They recommended involved field (IF) radiotherapy in low tumor burden localized disease, with adjuvant chemotherapy being reserved for cases of high tumor burden or high-risk disease (FLIPI score >2). The experts did not retain the eventualty of a “watchful waiting” option in a low burden case, which was associated with a good outcome in the Stanford experience [8]. More recently, a report mentioned that upfront RT was associated with improved OS compared with alternate management approaches.

© 2013 Michallet et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
At present, new low-toxicity therapies that prolong progression-free survival periods and the interval period to new anti-lymphoma therapies are available and include rituximab monotherapy or the combination of rituximab plus chemotherapy [12]. However, the impact of current therapies on early Stage FL is still unclear. The important question concerning the curability of this disease using a radical treatment remains unanswered.

We report the results of a retrospective study, including 145 patients diagnosed with localized-stage FL (stage I and II). These patients were treated with one of the six following options as first-line therapy in compliance with the physician's decision: watchful waiting (WW), chemotherapy alone (CT), radiotherapy alone (RT), a combination of radiotherapy and chemotherapy (RT-CT), immunotherapy alone (Ri), and immunochemotherapy (Ri-CT). With a median follow-up period of 7 years, we determined the clinical characteristics of each group and analyzed the overall and progression-free survival (OS and PFS) in order to determine the best approach.

Results and discussion

Of the 145 patients, 84 (57.9%) had Stage I disease and 61 (42.1%) Stage II. Only 22 (15.2%) presented bulky disease. Twelve patients were classified as having Stage IE or IIE. FLIPI scoring showed that 93% of the patients were in the low-risk group with a score of 0–2 (FLIPI score was 0–1 in 116 pts and 2 in 29 pts) and no patient had a score of >2.

Patient management significantly varied over the different time periods (Figure 1): Period I: <1990; Period II: 1991–2000, and Period III: 2001–2011. RT use decreased (43% for Period I versus 24% for Period III), whereas delayed therapy increased from 19.5% for Period I to 75% for Period III. The use of Ri and Ri-CT increased rapidly over Period III.

Watchful waiting strategy (WW)

Thirty-six patients (25 females and 11 males) did not receive any treatment at the time of diagnosis. The median age was 58 years, with 12 patients (33.3%) aged over 65 years. Twenty-two patients (61.1%) had stage I disease and 14 (38.9%) stage II disease, while no patients had bulky disease. Only two of these patients exhibited abnormal LDH levels.

Radiation therapy alone (RT)

Twenty-one patients (9 females and 12 males) were treated with RT alone. The median age was 51 years, with only four patients (19%) aged over 65 years. Seventeen patients (90.5%) had stage I disease and only two (9.5%) had stage II disease. None of them had bulky disease. Thirteen patients (65%) had a FLIPI score of 0, and five (30%) had a score of 1. No patient exhibited elevated β2-microglobulin levels or abnormal LDH levels. Five patients received extended RT and 16 received IF radiotherapy. Radiation doses ranged from 40 to 50Gy.

Chemotherapy alone (CT)

Twenty-six patients (12 females and 14 males) were treated with CT alone. The median age was 52.5 years, with eight patients (31%) aged over 60 years. Nine patients (34.6%) had stage I disease and 17 (65.4%) stage II, and the majority (17 patients) had no bulky disease. Twenty patients (77%) had normal LDH levels. In terms of the chemotherapy regimen, all patients received an anthracycline-containing regimen (CHOP or CHOP-like regimen).
Immunotherapy (Ri)
Only seven patients (4 females and 3 males) were treated with Ri alone as the single agent. Four injections were administered weekly with no further maintenance. The median age was 55 years, with 28.6% being older than 65. Three patients had stage I disease and four stage II. The majority of the patients had no bulky disease (71.4%).

Combination of chemotherapy and radiotherapy (CT-RT)
Eighteen patients (10 females and 9 males) were treated with various CT regimens (CHOP and CHOP-like regimens) plus RT. The median age was 51 years; none of these patients were older than 60 years. Seventeen (89.5%) had stage I disease and only 2 (10.5%) had stage II. The majority of patients (95%) had no bulky disease with a FLIPI score of 0. Fourteen patients had normal LDH levels. Three patients received additional extended RT, and 15 patients were given IF radiotherapy.

Immunochemotherapy (Ri-CT)
Thirty-six (17 males and 19 females) were treated with the combination of both Ri and CT, principally with the CHOP regimen. The median age was 56 years with only four patients being older than 65. Fifteen (41.7%) patients had bulky disease, and 17% had an abnormal LDH level at the time of diagnosis. Twenty-two patients had stage II (61%) disease and 14 stage I (39%).

Comparison of the six groups
Median age, sex ratio, number of patients over 60 years, stage of disease, and LDH levels were analyzed for the six groups (Table 1). There was a significant difference in terms of disease stage when comparing the RT based group (RT and RT+CT) group against the Ri based group (Ri-CT and Ri) with a large majority (90%) of Stage I disease in the RT-based groups (p=0.018) without any bulky disease (p= 0.05). Finally, the Ri-CT group had a higher number of adverse features: 41.7% of bulky disease and 16.7% of abnormal LDH levels.

Response rates and disease progression
The CR rate varied from 57.1% for Ri to 95% for the RT-CT group, with 69% for CT, 75% for Ri-CT, and 81% for RT alone, as shown in Table 2. As expected, the proportion of the PR was higher in the Ri group (43%). With a median follow-up interval of 7 years, the relapse rate was significantly lower in the Ri-CT group (40%) versus the RT-based group (90.5% for RT, 84% for RT-CT; p= 0.048); and 69% for CT as shown in Table 2.

Overall survival and progression-free survival
According to the changes in treatment management over time, OS, and PFS were analyzed for two periods of time (associated to the rituximab era): < the year 2000 and > or = 2000. As shown in Figure 2A and 2B, there was no difference in terms of OS or PFS at 5 years for the two time periods (85% vs. 87% and 48% vs. 42% respectively). Finally, we have shown a trend to a better OS at 7.5 years for the patients treated after 2000 (75%) than that for those treated <2000 (59%) but this difference is not statistically significant (p=0.29).

When considering PFS and OS according to the type of treatment, analyses did not show any difference in terms of OS at 7.5 years: 72% WW, 74% CT, 74% Ri-CT, 72% RT, 75% RT-CT, and 74% Ri.
67% RT-CT, 66% RT, and 100% Ri. By contrast, a significant difference was found for PFS at 7.5 years in favor of Ri-CT (60%) versus the others (19% RT, 26% RT-CT, 23% CT, and 26% for the WW strategy; p=0.00135), as shown in Figure 3.

Follicular lymphomas are slow-growing tumors with a relapsing and remitting course following treatment and usually result in death from the illness after several years. Although spontaneous regression may occur and progression may be slow, approximately 50% of patients undergo histological transformation to a more aggressive lymphoma with a poor prognosis [13]. In early-stage FL, the prospect of curing or, at least, maintaining long relapse-free survival often leads to treatment initiation [14]. On the other hand, the long life-expectancy of these patients, in spite of the disease, encourages treatment side-effects to be minimized as much as possible [6]. Nevertheless, while approximately 15 to 30% of patients with nodal or extra-nodal FL present clinical Stage I or II disease, therapy for early-stage FL offers a large number of possibilities: watchful waiting, single agent alkylating therapy, radiation therapy, CHOP regimen, and rituximab with various possible combinations. Defining the standard of care remains complex. In this retrospective study, we classified patients into six groups according to the treatments administered: abstention or delayed therapy, chemotherapy alone, radiotherapy alone, a combination of chemotherapy and radiotherapy, immunotherapy, and immunochemotherapy. RT alone is considered as the mainstay treatment showing long survival in some studies [3-5,15]. With a median follow-up period of 8 to 19 years, retrospective studies on RT have shown a 10-year PFS rate of 45% and 10-year OS rate of 65 to 75% [2,3,16,17]. These results do not differ from those observed in this analysis in terms of OS at 10 years (66% for the RT group and 62% for the RT-CT group). On the other hand, in our study, the PFS rate was lower than that reported in literature (around 25%); except for immunochemotherapy (60% PFS at 7.5 years) [3,16,17]. One explanation is the inherent limits of the retrospective setting and that some patients were referred to our center at the time of relapse.

The two issues surrounding radiation are field size and dose. The vast majority of early FL patients treated in retrospective series demonstrated excellent PFS following RT with involved field radiation, with a minority receiving extended field radiation. Recently, a randomized controlled trial of low- versus high-dose RT [18] for indolent non-Hodgkin's lymphoma demonstrated an equivalence of the two indolent lymphomas including early-stage FL with

| Table 2 Response to treatment, disease progression, and survival |
|------------------|------------------|------------------|------------------|------------------|------------------|
|                  | W and W CT       | Ri-CT            | RT-CT            | RT               | Ri               |
| Responses        |                  |                  |                  |                  |                  |
| CR               | 69.2%            | 75%              | 94.7%            | 80.9%            | 57.1%            |
| PR               | 19.2%            | 16.7%            | 5.3%             | 9.5%             | 42.9%            |
| SD               | 0                | 2.8%             | 0                | 0                | 0                |
| PD               | 11.6%            | 5.5%             | 0                | 9.5%             | 0                |
| Relapse rate     |                  |                  |                  |                  |                  |
| Median PFS 7.5y  | 26%              | 23%              | 60%              | 26%              | 19%              |
| Median OS 7.5y   | 72%              | 74%              | 74%              | 67%              | 66%              |

CR complete response, PR partial response, SD stable disease, PD progressive disease, OS overall survival, PFS progression free survival.

A. Overall Survival according to periods of time

B. Progression Free Survival according to periods of time

Figure 2 Disease progression and survival according to the period of time. A. Overall survival (OS) for two periods of time: <year 2000 and > or equal to 2000. B. Progression free survival (PFS) for to two periods of time, < 2000 and > or equal to 2000.
respect to response rate, PFS, and OS. Additionally, the prospective multicenter MIR (Mabthera and Involved field Radiation) study, which combines anti-CD20 antibody rituximab in combination with involved field radiotherapy (30–40 gray), evaluates the efficacy of rituximab in preventing out-filed recurrences as well as the safety of this combination [19].

Very few studies have looked at CT alone in localized FL [20]. As in our study, PFS did not differ for patients who received CT with or without RT (PFS at 7.5 years 23% for CT vs. 26% for combination RT-CT). The major question is whether immunochemotherapy improves the outcome for patients with early-stage FL. A recent analysis conducted by the National LymphoCare Study revealed, in a large prospectively enrolled group of patients with Stage I FL, that PFS was significantly improved with either rituximab-CT or systemic therapy plus RT when compared to RT alone [21].

**Conclusion**

One interesting observation in our study was that delayed therapy was associated with a similar outcome than that observed in treated patients (OS at 7.5 years for the different treatments and WW did not show any difference: 72% for WW compared to 74% for Ri-CT and 67% for RT-CT). This observation was previously reported in two retrospective studies [7,8]; the watchful waiting approach may thus be a reasonable strategy that does not affect OS (85% at 10 years) [22]. These results demonstrate that the choice of first-line treatment has no influence on the course of the disease, in contrast to patients receiving cytotoxic therapy, where the addition of rituximab improves OS [23]. However, when treatment is required, combined immunochemotherapy appears to be the best option. According to Montoto [24] and Friedberg et al. [21], the question of standard treatment in localized FL remains unresolved and requires well-designed randomized clinical trials.

**Patients and methods**

**Patient characteristics**

We analyzed 145 patients (pts) (79 females and 66 males), with a median age of 55 years (20% of patients aged >65 years) and a diagnosis of early-stage FL made between January 1967 and January 2011. All of these patients are either untreated patients with a diagnosis of FL made in our unit or referred to our unit in the relapse setting. With a median follow-up interval of 7 years and one month, diagnosis was based, in all cases, on a surgical specimen (lymph node or extra-nodal site biopsy). Histological reports provided the diagnosis in accordance with the World Health Organization (WHO) classification system. Patients with a histological WHO classification Grade 3b were excluded, as most experts would recommend a management plan identical to that of diffuse large B-cell lymphoma (DLBCL) [25].
Staging was designated according to the Ann Arbor system with “bulky disease” recording (>7 cm). Initial staging included a thoracic and abdominal CT scan, and a bone marrow aspirate and biopsy. PET CT has only been used in recent years. A complete blood count and routine blood chemistry testing, including LDH and β2-microglobulin levels, were performed. The Follicular Lymphoma International Prognostic Index (FLIPI) score was calculated based on individual parameters [26]. This index is based on five parameters with a poor outcome associated with age ≥60 years, hemoglobin <12 g/dl, LDH above normal range, Stage III/IV disease, and presence of ≥4 nodal sites, which is subdivided into low (0–1), intermediate (2), and high (≥3) risk groups.

Patients were retrospectively divided into six groups according to the initial therapeutic strategy that was applied: WW, CT alone, RT alone, RT-CT, RI alone, and RI-CT. The initial treatment was decided upon by the attending physician following discussion with the patient. Clinical and biological patient characteristics are summarized in Table 1.

Statistical analysis
Statistical analyses were performed using SPSS software version 12.0. Demographic characteristics were compared across the groups using chi-squared tests for qualitative characteristics, while the t-test, Mann–Whitney test, and ANOVA test were used for quantitative characteristics. The event-free survival (EFS) and the OS were calculated according to the Kaplan-Meier product limit estimator method. Survival was calculated from the time of diagnosis to death for any given case. PFS was calculated from the time of diagnosis to the moment of progression or relapse. Univariate comparisons of survival curves were made using the log-rank test. Two side P-values of <0.05 were considered statistically significant.

Competing interests
The authors indicated no potential conflicts of interest to declare in relation to this manuscript.

Authors’ contributions
Conception and design: A-SM, GS, and BC. Provision of study materials or patients: All co-authors. Collection and assembly of data: A-SM, DB, and LL. Data analysis and interpretation: A-SM, LL, GS, and BC. Manuscript writing: A-SM, GS, and BC. Final approval of the manuscript: all co-authors.

Author details
1 Department of Hematology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France. 2 Université de Lyon, Faculté de Médecine Lyon-Sud Charles Mérieux, Pierre Bénite, France. 3 Clinique Universitaire Saint Luc, UCL, Woluwe Saint Laurent, Belgium. 4 Department of Anatomopathology, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France. 5 Department of Radiotherapy, Hospices Civils de Lyon, Centre Hospitalier Lyon Sud, Pierre Bénite, France. 6 Service d’Hématologie Clinique, Centre Hospitalier Lyon Sud, 165 chemin du Grand Revoyet, F-69310 Pierre Bénite, France.

Received: 14 April 2013 Accepted: 26 June 2013
Published: 1 July 2013

References
1. Peterson CG, Kah B: Follicular lymphoma: management options in the era of targeted therapy. Current treatment options in oncology 2005, 6:297–308.
2. Wilder RB, Jones D, Tucker SJ, et al: Long-term results with radiotherapy for Stage III follicular lymphomas. International journal of radiation oncology, biology, physics 2001, 51:1219–1227.
3. Mac Manus NP, Hoppe RT: Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 1996, 14:1282–1290.
4. Vaughan Hudson B, Vaughan Hudson G, MacLennan KA, et al: Clinical stage I non-Hodgkin’s lymphoma: long-term follow-up of patients treated by the British National Lymphoma Investigation with radiotherapy alone as initial therapy. British journal of cancer 1994, 69:1088–1093.
5. Yialomot V, Varois G, Fuku Z, et al: Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study. Cancer 1993, 72:2342–2350.
6. Seymour JF, Pro B, Fuller LM, et al: Long-term follow-up of a prospective study of combined modality therapy for stage I-I indolent non-Hodgkin’s lymphoma. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2003, 21:115–2122.
7. Sobeyyan P, Eghbali H, Trojani M, et al: Is there any place for a wait-and-see policy in stage I follicular lymphoma? A study of 43 consecutive patients in a single center. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 1996, 7:713–718.
8. Advani R, Rosenberg SA, Horning SJ: Stage I and II follicular non-Hodgkin’s lymphoma: long-term follow-up of no initial therapy. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2004, 22:1454–1459.
9. Dreyling M: Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2010, 21(Suppl 5):v181–183.
10. Banos G, Carella A, Lazzarino M, et al: Management of nodal indolent (non marginal-zone) non-Hodgkin’s lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2005, 90:1236–1257.
11. Pugh T, Ballonoff A, Newman F, Rabinovitch R: Improved survival in patients with early stage low-grade follicular lymphoma treated with radiation: a Surveillance, Epidemiology, and End Results database analysis. Cancer 2010, 116:3843–3851.
12. Dreyling M, Ghielmini M, Marcus R, et al: Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology: official journal of the European Society for Medical Oncology/ESMO 2011, 22(Suppl 6):s59–63.
13. Baston Y, Sebban C, Berger F, et al: Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 1997, 15:1587–1594.
14. Gandhi MK, Marcus RE: Follicular lymphoma: time for a re-think? Blood reviews 2005, 19:165–175.
15. Kamath SS, Marcus RR Jr, Lynch JW, Mendenhall NP: The impact of radiotherapy dose and other treatment-related and clinical factors on in-field control in stage I and II non-Hodgkin’s lymphoma. International journal of radiation oncology, biology, physics 1999, 44:563–568.
16. Guadagnolo BA, Li S, Neuberg D, et al: Long-term outcome and mortality trends in early-stage, Grade 1–2 follicular lymphoma treated with radiotherapy therapy. International journal of radiation oncology, biology, physics 2006, 64:928–934.
17. Campbell BA, Voss N, Woods R, et al: Long-term outcomes for patients with limited stage follicular lymphoma: involved regional radiotherapy versus involved node radiotherapy. Cancer 2010, 116:3797–3806.
18. Lovly L, Smith P, Qian W, et al: Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: a randomised phase III trial.
19. Witzens-Harig M, Hensel M, Unterhalt M, Herfarth K: Treatment of limited stage follicular lymphoma with Rituximab immunotherapy and involved field radiotherapy in a prospective multicenter Phase II trial-MIR trial. BMC cancer 2011, 11:87.

20. Kelsey SM, Newland AC, Hudson GV, Jelliffe AM: A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma. Medical oncology 1994, 11:19–25.

21. Friedberg JW, Byrtek M, Link BK, et al: Effectiveness of First-Line Management Strategies for Stage I Follicular Lymphoma: Analysis of the National LymphoCare Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2012, 30:3368–3375.

22. Solal-Celigny P, Bellei M, Marcheselli L, et al: Watchful Waiting in Low-Tumor Burden Follicular Lymphoma in the Rituximab Era. official journal of the American Society of Clinical Oncology: Results of an F2-Study Database. Journal of clinical oncology; 2012.

23. Schulz H, Bohlius JF, Trelle S, et al: Immunochemotherapy with rituximab and overall survival in patients with indolent or mantle cell lymphoma: a systematic review and meta-analysis. Journal of the National Cancer Institute 2007, 99:706–714.

24. Montoto S: Management of localized-stage follicular lymphoma: changing the paradigm? Journal of clinical oncology: official journal of the American Society of Clinical Oncology 2012, 30:3328–3329.

25. Ott G, Katzenberger T, Lohr A, et al: Cytomorphologic, immunohistochemical, and cytogenetic profiles of follicular lymphoma: 2 types of follicular lymphoma grade 3. Blood 2002, 99:3806–3812.

26. Solal-Celigny P, Roy P, Colombat P, et al: Follicular lymphoma international prognostic index. Blood 2004, 104:1258–1265.

doi:10.1186/1756-8722-6-45

Cite this article as: Michallet et al.: Early stage follicular lymphoma: what is the clinical impact of the first-line treatment strategy?. Journal of Hematology & Oncology 2013 6:45.